Screener
Ligand Pharmaceuticals LGND Cash Flow Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| -$28.49M-124% | $48.51M+901% | -$13.35M+68.6% | $44.78M+244% | $117.27M+1,735% | ||
| $10.32M+24.8% | $8.22M-3.6% | $8.22M-6.3% | $8.21M-4.8% | $8.27M-8.1% | ||
| $18.18M+23.3% | $13.65M+36.6% | $10.6M+35.2% | $14.27M+89.7% | $14.75M-2.8% | ||
| —— | $24.02M+52.0% | $48.69M+291% | $45.92M+61.3% | $13.09M-64.2% | ||
| $142K+847% | $26K-87.9% | $228K+6.5% | $9K-98.7% | $15K-97.5% | ||
| -$877.99M-148% | $321.12M+3,110% | -$94.35M-2,028% | -$18.1M+53.1% | -$353.45M-660% | ||
| —— | —— | —— | —— | $15M— | ||
| —— | —— | —— | —— | $460M— | ||
| $4.06M-99.0% | $546.43M+3,544% | -$14.13M-198% | $8.33M-59.1% | $409.65M+644% | ||
| -$903.31M-1,360% | $891.61M+4,431% | -$59.83M-146% | $35.55M+309% | $71.71M+57.7% |
FAQ
- Where does Ligand Pharmaceuticals's cash flow data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
